Iovance Biotherapeutics, Inc. (IOVA): Total Liabilities
$214.59M
As of 2025-12-31
$179.49M
As of 2026-06-30
+9.3%
3-year compound annual growth
+13.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $214.59M | +7.3% | 2026-02-24, Balance as of period end |
| 2024-12-31 | $200.02M | +2.2% | 2026-02-24, Balance as of period end |
| 2023-12-31 | $195.74M | +19.1% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $164.34M | +5.6% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $155.67M | +39.0% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $111.96M | +145.1% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $45.68M | +212.3% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $14.63M | +47.9% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $9.89M | n/a | 2019-02-28, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $214.59M | +7.3% |
| Vericel Corp (VCEL) | 2025-12-31 | $133.33M | -5.3% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $287.74M | -14.6% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $98.28M | -8.5% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $168.90M | +19.3% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $114.23M | +4.4% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $234.11M | -3.7% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $686.24M | +5.8% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $350.30M | +69.8% |
Compare IOVA, VCEL, ADPT, VXRT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗